WPRIM Management System> DCMS> Clinical and Molecular Hepatology> 2020> 26> 3

Volume: 26 Issue: 3

1. Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? Page:312—314
2. Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma Page:305—308
3. Is liver biopsy still useful in the era of non-invasive tests? Page:302—304
4. Macro-aspartate aminotransferase in a healthy woman Page:378—381
5. Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change? Page:315—317
6. Fecal microbiota transplantation in alcohol related liver diseases Page:294—301
7. Management of liver diseases during the pandemic of coronavirus disease-19 Page:243—250
8. Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria? Page:309—311
9. Novel biomarkers for the management of chronic hepatitis B Page:261—279
10. How does low-level viremia affect the prognosis of patients with chronic hepatitis B? Page:376—377
11. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging Page:340—351
12. Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis Page:280—293
13. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir Page:364—375
14. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response Page:352—363
15. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment Page:328—339
16. Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years Page:318—327
17. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy Page:251—260